| scholarly article | Q13442814 |
| P50 | author | Nicolas Chapuis | Q51322110 |
| Valérie Bardet | Q56167780 | ||
| Norbert Ifrah | Q56549745 | ||
| Lise Willems | Q43144891 | ||
| Jerome Tamburini | Q48282150 | ||
| Didier Bouscary | Q48282168 | ||
| P2093 | author name string | François Dreyfus | |
| Sophie Park | |||
| Catherine Lacombe | |||
| Patrick Mayeux | |||
| Alexa S Green | |||
| Madalina Uzunov | |||
| P433 | issue | 8 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | sirolimus | Q32089 |
| leukemia | Q29496 | ||
| P304 | page(s) | 1618-1627 | |
| P577 | publication date | 2009-05-20 | |
| P1433 | published in | Blood | Q885070 |
| P1476 | title | Protein synthesis is resistant to rapamycin and constitutes a promising therapeutic target in acute myeloid leukemia | |
| P478 | volume | 114 |
| Q36838384 | 4E-BP1, a multifactor regulated multifunctional protein |
| Q36965860 | 4EBP1/c-MYC/PUMA and NF-κB/EGR1/BIM pathways underlie cytotoxicity of mTOR dual inhibitors in malignant lymphoid cells. |
| Q36926129 | A combination of temsirolimus, an allosteric mTOR inhibitor, with clofarabine as a new therapeutic option for patients with acute myeloid leukemia |
| Q52571251 | A novel, dual pan-PIM/FLT3 inhibitor SEL24 exhibits broad therapeutic potential in acute myeloid leukemia. |
| Q45731131 | A phase Ib GOELAMS study of the mTOR inhibitor RAD001 in association with chemotherapy for AML patients in first relapse. |
| Q34140027 | A small molecule inhibitor of Pim protein kinases blocks the growth of precursor T-cell lymphoblastic leukemia/lymphoma |
| Q39463725 | AMP-dependent kinase/mammalian target of rapamycin complex 1 signaling in T-cell acute lymphoblastic leukemia: therapeutic implications. |
| Q37564783 | AZD1208, a potent and selective pan-Pim kinase inhibitor, demonstrates efficacy in preclinical models of acute myeloid leukemia |
| Q38003091 | Anti-oncogenic potential of the eIF4E-binding proteins |
| Q43461214 | Antileukaemic effect of PI3K-mTOR inhibitors in acute myeloid leukaemia-gene expression profiles reveal CDC25B expression as determinate of pharmacological effect |
| Q38259991 | Biological effects of the Pim kinase inhibitor, SGI-1776, in multiple myeloma |
| Q46315733 | Characterizing the in vitro species differences in N-glucuronidation of a potent pan-PIM inhibitor GNE-924 containing a 3,5-substituted 6-azaindazole |
| Q36337587 | Co-administration of the mTORC1/TORC2 inhibitor INK128 and the Bcl-2/Bcl-xL antagonist ABT-737 kills human myeloid leukemia cells through Mcl-1 down-regulation and AKT inactivation. |
| Q36746585 | Combination of Pim kinase inhibitors and Bcl-2 antagonists in chronic lymphocytic leukemia cells |
| Q64111923 | Combined Treatment with Doxorubicin and Rapamycin Is Effective against In Vitro and In Vivo Models of Human Glioblastoma |
| Q34666165 | Concurrent inhibition of PI3K and mTORC1/mTORC2 overcomes resistance to rapamycin induced apoptosis by down-regulation of Mcl-1 in mantle cell lymphoma |
| Q34354609 | Constitutive phosphorylation of the mTORC2/Akt/4E-BP1 pathway in newly derived canine hemangiosarcoma cell lines |
| Q36353641 | Control of Pim2 kinase stability and expression in transformed human haematopoietic cells |
| Q42319925 | Control of translational activation by PIM kinase in activated B-cell diffuse large B-cell lymphoma confers sensitivity to inhibition by PIM447. |
| Q37195321 | Downregulation of p70S6K Enhances Cell Sensitivity to Rapamycin in Esophageal Squamous Cell Carcinoma |
| Q54315033 | Dual PI3K/mTOR inhibition shows antileukemic activity in MLL-rearranged acute myeloid leukemia. |
| Q38797046 | Dual mTORC1/2 inhibition induces anti-proliferative effect in NF1-associated plexiform neurofibroma and malignant peripheral nerve sheath tumor cells. |
| Q35091507 | Dual mTORC2/mTORC1 targeting results in potent suppressive effects on acute myeloid leukemia (AML) progenitors |
| Q58745901 | ETV7 is an essential component of a rapamycin-insensitive mTOR complex in cancer |
| Q38803880 | Elevated PIM2 gene expression is associated with poor survival of patients with acute myeloid leukemia. |
| Q38227377 | Eukaryotic translation initiation factor 4E as a novel therapeutic target in hematological malignancies and beyond |
| Q37906986 | Evi1 forms a bridge between the epigenetic machinery and signaling pathways. |
| Q91996647 | Exploiting metabolic vulnerabilities for personalized therapy in acute myeloid leukemia |
| Q37638749 | FLT3 inhibitors: clinical potential in acute myeloid leukemia. |
| Q38892684 | FLT3-ITD confers resistance to the PI3K/Akt pathway inhibitors by protecting the mTOR/4EBP1/Mcl-1 pathway through STAT5 activation in acute myeloid leukemia |
| Q52366350 | FLT3-ITD induces expression of Pim kinases through STAT5 to confer resistance to the PI3K/Akt pathway inhibitors on leukemic cells by enhancing the mTORC1/Mcl-1 pathway. |
| Q34105627 | Flavaglines target primitive leukemia cells and enhance anti-leukemia drug activity. |
| Q37820056 | For better or for worse: the role of Pim oncogenes in tumorigenesis |
| Q42153541 | Gene expression-based risk score in diffuse large B-cell lymphoma |
| Q35238980 | Genistein exerts anti-leukemic effects on genetically different acute myeloid leukemia cell lines by inhibiting protein synthesis and cell proliferation while inducing apoptosis - molecular insights from an iTRAQ™ quantitative proteomics study. |
| Q51103239 | High mTORC1 activity drives glycolysis addiction and sensitivity to G6PD inhibition in acute myeloid leukemia cells. |
| Q51051812 | Hyperactivation of mTORC1 and mTORC2 by multiple oncogenic events causes addiction to eIF4E-dependent mRNA translation in T-cell leukemia. |
| Q37778876 | Inflammation and survival pathways: chronic lymphocytic leukemia as a model system |
| Q37311260 | Inhibiting glutamine uptake represents an attractive new strategy for treating acute myeloid leukemia. |
| Q90397981 | Inhibition of esophageal cancer growth through the suppression of PI3K/AKT/mTOR signaling pathway |
| Q39326047 | Inhibition of mTOR kinase as a therapeutic target for acute myeloid leukemia |
| Q36899877 | Inhibition of mTORC2 Induces Cell-Cycle Arrest and Enhances the Cytotoxicity of Doxorubicin by Suppressing MDR1 Expression in HCC Cells |
| Q37437166 | Intrinsic resistance to PIM kinase inhibition in AML through p38α-mediated feedback activation of mTOR signaling |
| Q34750609 | Leukemic cell xenograft in zebrafish embryo for investigating drug efficacy. |
| Q55311942 | Mechanisms for mTORC1 activation and synergistic induction of apoptosis by ruxolitinib and BH3 mimetics or autophagy inhibitors in JAK2-V617F-expressing leukemic cells including newly established PVTL-2. |
| Q34979869 | Metformin induces apoptosis through AMPK-dependent inhibition of UPR signaling in ALL lymphoblasts |
| Q34485116 | Noncytotoxic Inhibition of Viral Infection through eIF4F-Independent Suppression of Translation by 4EGi-1 |
| Q38521775 | Outlook on PI3K/AKT/mTOR inhibition in acute leukemia |
| Q34164683 | PI3K and mTOR signaling pathways in cancer: new data on targeted therapies |
| Q24603099 | PIM serine/threonine kinases in the pathogenesis and therapy of hematologic malignancies and solid cancers |
| Q37779489 | Perspectives on inhibiting mTOR as a future treatment strategy for hematological malignancies |
| Q28271318 | Pim kinase inhibitors: a survey of the patent literature |
| Q36276942 | Pim kinases modulate resistance to FLT3 tyrosine kinase inhibitors in FLT3-ITD acute myeloid leukemia |
| Q39142229 | Pim kinases phosphorylate Chk1 and regulate its functions in acute myeloid leukemia |
| Q55496770 | Preclinical characterization of INCB053914, a novel pan-PIM kinase inhibitor, alone and in combination with anticancer agents, in models of hematologic malignancies. |
| Q37431583 | Proliferation and survival signaling from both Jak2-V617F and Lyn involving GSK3 and mTOR/p70S6K/4EBP1 in PVTL-1 cell line newly established from acute myeloid leukemia transformed from polycythemia vera |
| Q47797184 | RSK2 is a new Pim2 target with pro-survival functions in FLT3-ITD-positive acute myeloid leukemia. |
| Q54517713 | Rapamycin enhances dimethyl sulfoxide-mediated growth arrest in human myelogenous leukemia cells. |
| Q33852446 | Recent advances in the discovery of small molecule mTOR inhibitors |
| Q37811200 | Regulation and deregulation of mRNA translation during myeloid maturation |
| Q35758763 | Ribavirin Inhibits the Activity of mTOR/eIF4E, ERK/Mnk1/eIF4E Signaling Pathway and Synergizes with Tyrosine Kinase Inhibitor Imatinib to Impair Bcr-Abl Mediated Proliferation and Apoptosis in Ph+ Leukemia |
| Q37642294 | Role of the PI3K/AKT and mTOR signaling pathways in acute myeloid leukemia. |
| Q37865381 | Roles of the Ras/Raf/MEK/ERK pathway in leukemia therapy. |
| Q36688940 | SNS-032 inhibits mTORC1/mTORC2 activity in acute myeloid leukemia cells and has synergistic activity with perifosine against Akt. |
| Q33641643 | SYK regulates mTOR signaling in AML. |
| Q35836566 | Single-cell pharmacodynamic monitoring of S6 ribosomal protein phosphorylation in AML blasts during a clinical trial combining the mTOR inhibitor sirolimus and intensive chemotherapy |
| Q27684773 | Structure of the eukaryotic translation initiation factor eIF4E in complex with 4EGI-1 reveals an allosteric mechanism for dissociating eIF4G |
| Q38995037 | Synthesis of rigidified eIF4E/eIF4G inhibitor-1 (4EGI-1) mimetic and their in vitro characterization as inhibitors of protein-protein interaction |
| Q43175143 | T-ALL: ALL a matter of Translation? |
| Q39590044 | Targeted inhibition of mTORC1 and mTORC2 by active-site mTOR inhibitors has cytotoxic effects in T-cell acute lymphoblastic leukemia. |
| Q38333251 | Targeted therapy of acute myeloid leukemia |
| Q99549077 | Targeting PI3K/Akt/mTOR in AML: Rationale and Clinical Evidence |
| Q57461994 | Targeting STAT5 or STAT5-Regulated Pathways Suppresses Leukemogenesis of Ph+ Acute Lymphoblastic Leukemia |
| Q36446451 | Targeting TORC1/2 enhances sensitivity to EGFR inhibitors in head and neck cancer preclinical models. |
| Q34130816 | Targeting eukaryotic translation initiation factor 4E (eIF4E) in cancer |
| Q34173253 | Targeting the translational apparatus to improve leukemia therapy: roles of the PI3K/PTEN/Akt/mTOR pathway |
| Q33747291 | Targeting the translational machinery as a novel treatment strategy for hematologic malignancies |
| Q38699320 | Targeting translation: eIF4E as an emerging anticancer drug target |
| Q38098139 | The PIM family of serine/threonine kinases in cancer |
| Q28258028 | The PIM kinases in hematological cancers |
| Q39000582 | The Pim-1 protein kinase is an important regulator of MET receptor tyrosine kinase levels and signaling |
| Q39363181 | The cap-translation inhibitor 4EGI-1 induces apoptosis in multiple myeloma through Noxa induction. |
| Q50506558 | The dual mTORC1 and mTORC2 inhibitor AZD8055 has anti-tumor activity in acute myeloid leukemia. |
| Q50510141 | The eukaryotic initiating factor 4E protein is overexpressed, but its level has no prognostic impact in acute myeloid leukaemia. |
| Q34494886 | The mRNA-binding protein HuR promotes hypoxia-induced chemoresistance through posttranscriptional regulation of the proto-oncogene PIM1 in pancreatic cancer cells. |
| Q36842143 | The oncogene eIF4E: using biochemical insights to target cancer |
| Q34024558 | The phosphatidylinositol 3-kinase/Akt/mTOR signaling network as a therapeutic target in acute myelogenous leukemia patients. |
| Q50027679 | Therapeutic Opportunities in Eukaryotic Translation |
| Q90230633 | Therapeutic Use of mTOR Inhibitors in Renal Diseases: Advances, Drawbacks, and Challenges |
| Q37837732 | Therapeutic resistance resulting from mutations in Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR signaling pathways. |
| Q39283981 | Transcription and translation are primary targets of Pim kinase inhibitor SGI-1776 in mantle cell lymphoma |
| Q36555212 | Translational control in cancer etiology |
| Q37717999 | Translational control in cancer. |
| Q34260622 | Two hits are better than one: targeting both phosphatidylinositol 3-kinase and mammalian target of rapamycin as a therapeutic strategy for acute leukemia treatment. |
| Q28078957 | Will targeting PI3K/Akt/mTOR signaling work in hematopoietic malignancies? |
| Q53477547 | [Co-activation of AMPK and mTORC1: a therapeutic application of synthetic lethality in acute myeloid leukemia]. |
| Q27007511 | mTOR Signaling in Protein Translation Regulation: Implications in Cancer Genesis and Therapeutic Interventions |
| Q41716371 | mTOR kinase-dependent, but raptor-independent regulation of downstream signaling is important for cell cycle exit and myogenic differentiation |
Search more.